Damian Chaupin in Miami, Florida

Medical School: Boston University School Of Medicine
Graduation Year: 2003
The Primary Medical Specialty for Damian Chaupin is listed as: Cardiovascular Disease (cardiology)
Approximate Years of Experience: 21
PAC (PECOS ID)#: 6709932338
NPI #: 1891950150
NPI Created On: 07/25/2008
NPI Last Updated Listed as: 07/15/2022
Primary Taxonomy Code: 207RC0000X
License Number:
103261
Listed Gender: Male

Forms of insurance accepted by include, but are not limited to:

• Molina Healthcare of Florida, Inc
• Blue Cross Blue Shield
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Nuclear medicine study of vessels of heart using drugs or exercise multiple studies
2. Routine ekg using at least 12 leads including interpretation and report
3. Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report
4. Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report
5. Heart rhythm tracing of 48-hour ekg
6. Heart rhythm tracing, analysis, and interpretation of 48-hour ekg
7. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
8. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
9. Follow-up or limited ultrasound examination of heart
10. New patient office or other outpatient visit, typically 45 minutes
11. Established patient office or other outpatient visit, typically 15 minutes
12. Established patient office or other outpatient, visit typically 25 minutes
13. Initial hospital inpatient care, typically 50 minutes per day
14. Initial hospital inpatient care, typically 70 minutes per day
15. Subsequent hospital inpatient care, typically 25 minutes per day
16. Subsequent hospital inpatient care, typically 35 minutes per day
17. Physician telephone patient service, 21-30 minutes of medical discussion
18. Technetium tc-99m sestamibi, diagnostic, per study dose
19. Injection, regadenoson, 0.1 mg